May 27, 2026 08:01AM
May 27, 2026 08:00AM
Apr 29, 2026 07:00AM
Apr 8, 2026 08:00AM
Mar 18, 2026 08:32AM
Mar 18, 2026 08:30AM
Mar 16, 2026 08:15AM Amarin to present new REDUCE-IT data at cardiology conference
Mar 16, 2026 08:15AM
Mar 16, 2026 08:15AM
Mar 2, 2026 08:00AM
Feb 25, 2026 07:00AM
Feb 23, 2026 08:00AM
Jan 9, 2026 07:03AM
Jan 9, 2026 07:00AM Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Cate
Jan 8, 2026 07:00AM
Nov 9, 2025 04:15PM
Nov 3, 2025 08:32AM
Nov 3, 2025 08:30AM
Oct 30, 2025 05:38AM
Oct 29, 2025 07:00AM
Oct 27, 2025 08:00AM Amarin supports FDA fenofibrate label revision showing no heart benefit
Oct 27, 2025 08:00AM
Oct 14, 2025 08:06AM
Oct 14, 2025 08:00AM
Aug 31, 2025 08:30AM
Aug 30, 2025 08:30AM
Aug 30, 2025 08:30AM
Aug 25, 2025 08:00AM New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
Jul 30, 2025 07:00AM
Jun 24, 2025 07:00AM
Jun 24, 2025 07:00AM
May 7, 2025 07:00AM
Mar 31, 2025 08:00AM
Mar 19, 2025 07:33AM
Mar 19, 2025 07:30AM New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Recepto
Mar 19, 2025 07:30AM
Mar 12, 2025 07:00AM
Mar 12, 2025 07:00AM
Feb 27, 2025 09:00AM
Nov 11, 2024 08:00AM
Oct 30, 2024 04:05PM
Oct 8, 2024 07:00AM Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
Sep 9, 2024 07:30AM
Aug 22, 2024 08:31AM
Aug 22, 2024 08:30AM
Jul 31, 2024 07:00AM
Jul 8, 2024 07:30AM
Jul 8, 2024 07:30AM
Jul 8, 2024 07:30AM Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
Jun 24, 2024 04:01PM

323,547 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All